Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy

Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy

Tolvaptan, an oral vasopressin V2 receptor antagonist, reduces renal volume expansion and loss of renal function in patients with autosomal dominant polycystic kidney disease (ADPKD). Data for predictive factors indicating patients more likely to benefit from long-term tolvaptan are lacking. Data we...

Full description

Bibliographic Details
Main Authors: Mai Yamazaki, Haruna Kawano, Miho Miyoshi, Tomoki Kimura, Keiji Takahashi, Satoru Muto, Shigeo Horie
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:International Journal of Molecular Sciences
Subjects:
ADPKD
tolvaptan
BMI
biomarkers
family history
Online Access:https://www.mdpi.com/1422-0067/25/4/2088

Internet

https://www.mdpi.com/1422-0067/25/4/2088

Similar Items